WEGO

WEGO was founded in 1988, starting its business with a tax revolving fund of 25,000 yuan and disposable infusion sets. Currently, the company focuses on developing its core businesses of medical devices and pharmaceuticals while also expanding into construction, finance, and other industries. WEGO Holding Company oversees WEGO Group, WEGO Construction Industry Group, and WEGO Financial Holdings Group, covering an area of over 6 million square meters with more than 80 subsidiaries and two publicly listed companies, employing over 30,000 people. WEGO Group includes seven industrial groups: medical products, blood purification, orthopedics, medical equipment, pharmaceuticals, cardiovascular consumables, and medical commerce. The Construction Industry Group primarily engages in real estate, building materials, hotels, food, and tourism; the Financial Holdings Group mainly handles asset and capital management, credit, equity investment, and securities management. It offers more than 1,000 varieties and 150,000 specifications of products including infusion consumables and equipment, blood transfusion equipment, cardiovascular consumables, indwelling needles and various specialty needles, blood purification equipment and consumables, orthopedic materials, surgical equipment and accessories, trauma care, surgical robots, minimally invasive instruments and equipment, ICU products and accessories, large-volume injections and other medicines, nephrology products, biological diagnostic reagents, surgical sutures, dental implants, infection control equipment and consumables, PVC and non-PVC raw materials, etc. Its medical devices have entered 11 out of the 15 global sub-markets, making it a comprehensive medical system solutions provider known for its wide range of products, safety, and reliability. It has received numerous honors including being named an 863 Industrialization Base, a Key High-Tech Enterprise under the National Torch Program, a National Intellectual Property Demonstration Enterprise, an industry leader, one of China's Top 500 Enterprises, one of China’s Top 500 Credit Enterprises, one of China’s Top 500 Private Enterprises, a National Contract-abiding and Credit-worthy Enterprise, a National Independent Innovation Demonstration Unit, recipient of the National May 1 Labor Medal, the China Industry Award, a National Model Enterprise for Implementing Excellence Performance, winner of the Shandong Governor's Quality Award, nominee for the China Quality Award, and recipient of the Global Excellence Performance Award. Weihai Lanhai Bank operates with approval from the China Banking Regulatory Commission. In 2020, it ranked 375th among China's Top 500 Enterprises, 176th among China's Top 500 Manufacturing Enterprises, 165th among China's Top 500 Private Enterprises, and 92nd among China's Top 500 Private Manufacturing Enterprises.The company vigorously improves its innovation system, establishing platforms such as a nationally recognized enterprise technology center, the National Engineering Laboratory for Implantable Devices, a national innovative pilot enterprise, academician workstations, post-doctoral workstations, the Shandong High-Performance Medical Device Research Center, the Shandong Medical Device Technology Innovation Center, provincial engineering and technology research centers, and Taishan Scholar Laboratories. It is accelerating the development of three major platforms: the WEGO Research Institute, the National Innovation Center Platform, and R&D centers in Beijing and Changchun. Collaborating with over 30 renowned universities and research institutes such as the Chinese Academy of Sciences, the Chinese Academy of Engineering, the Academy of Military Medical Sciences, the 301 Hospital, Harbin Institute of Technology, and Tianjin University, it has established more than 30 R&D institutions. The company owns over 1,100 patents, including more than 400 invention patents, and over 900 products with independent intellectual property rights. More than 80% of its products are high-tech and high value-added, including over 100 products like orthopedic material series, blood purification series, cardiovascular consumables series, artificial liver, fully automatic chemiluminescence analyzers, color Doppler ultrasound, DR, prefilled syringes, membrane oxygenators, and Protein A immunoadsorption columns that have broken foreign monopolies to become internationally renowned brands. Thirty items have been included in national projects like the National Torch Program and the "863 Program," winning four National Science and Technology Progress Awards and National Technology Invention Awards (for polyolefin materials, infusion and interventional technologies, cardiac drug-coated stent technology, and new battlefield critical chest trauma rescue techniques). Its minimally invasive surgical robot won the Gold Award of China's Excellent Industrial Design Award.